Welcome to our dedicated page for Usana Health Sciences SEC filings (Ticker: USNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
USANA Health Sciences, Inc. (NYSE: USNA) files a range of documents with the U.S. Securities and Exchange Commission that provide detail on its nutrition-focused business, financial condition, and governance. This page centralizes those SEC filings and pairs them with AI-powered summaries to help readers interpret the information more efficiently.
USANA’s current reports on Form 8-K include disclosures about preliminary financial results, updated net sales guidance, and leadership transitions, such as changes in the Chief Executive Officer role. Other 8-K filings describe credit agreements, financial covenants, and the posting of Management Commentary documents and conference call details related to quarterly results. These filings complement the company’s earnings releases and provide context on how management views performance in its direct selling and direct-to-consumer segments.
Investors can also use this page to access USANA’s periodic reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q, where available. These documents typically contain segment information, risk factor discussions, and explanations of non-GAAP measures such as Adjusted EBITDA and Adjusted diluted earnings per share, which USANA references in its communications.
Stock Titan’s platform enhances these filings with AI-generated highlights that explain key sections, summarize complex tables, and surface notable items such as changes in outlook, capital structure, or significant agreements. Users can quickly locate information on topics like net sales trends, credit facilities, or integration costs related to acquisitions such as Hiya, and can review insider-related disclosures when Forms 3, 4, or 5 are filed. Real-time updates from EDGAR help ensure that new USANA filings appear promptly with concise explanations.
USANA Health Sciences, Inc. reported a leadership transition in which Jim Brown has stepped down as Chief Executive Officer and President, effective January 8, 2026. He will remain with the company in an advisory role for a period at the discretion of the Board of Directors, providing some continuity during the change.
Kevin Guest, age 63, who currently serves as Executive Chairman of the Board and previously served as Chief Executive Officer, will reassume the role of Chief Executive Officer while continuing as Chairman. The company states there is no arrangement or understanding with any other person regarding his selection, and no family or related-party relationships requiring additional disclosure. The Compensation Committee has not yet determined the compensation arrangements for Mr. Brown’s separation or for Mr. Guest’s new role as Chief Executive Officer and expects to decide these shortly, after which an amendment will be filed. The company has issued a press release describing these changes.
USANA Health Sciences Inc. insider reports small stock sale. The company’s Chief Sales Officer filed a Form 4 disclosing the sale of 873 shares of USANA common stock on 12/10/2025. The shares were sold at a price of $21 per share, using transaction code “S,” which indicates an open market or private sale.
After this transaction, the officer beneficially owns 8,387 shares of USANA common stock in direct ownership. The filing is made by a single reporting person and does not report any derivative securities activity.
USANA Health Sciences Inc. (USNA) reported an insider stock transaction by its Chief Information Officer. On 12/10/2025, the officer sold 2,673 shares of common stock in an open market transaction at a price of $20.9506 per share, coded as a sale ("S"). After this transaction, the reporting person held 0 shares of USANA common stock in direct ownership. The filing covers only non-derivative common stock, with no derivative securities reported.
USANA Health Sciences filed a notice under Rule 144 for a planned sale of restricted common stock. The filing covers 2,673 shares of common stock, with an aggregate market value of $56,000.95, to be sold through Morgan Stanley Smith Barney LLC on the NYSE. The issuer had 18,280,857 shares of common stock outstanding. The shares were acquired from the issuer as restricted stock in several transactions dated between February 6, 2025 and July 25, 2025. The seller represents that they are not aware of any material adverse, nonpublic information about the company’s current or prospective operations.
USANA Health Sciences (USNA) Form 4: A director reported an open-market sale of common stock. On 11/10/2025, the director sold 2,000 shares (transaction code S) at a price of $19.21 per share. Following this transaction, the director beneficially owns 5,986 shares, held directly.
USANA Health Sciences reported Q3 2025 net sales of $213.7 million, up 6.7% year over year, driven by the addition of the Hiya direct‑to‑consumer business ($30.8 million) and growth in “Other,” which offset declines in direct selling.
The quarter showed a net loss of $6.5 million versus earnings of $10.6 million a year ago. Management cites a sharp increase in the annualized effective tax rate to 65% and higher selling, general and administrative costs, including amortization of acquired intangibles and elevated marketing at Hiya. Gross margin was 77.2% (down 320 bps), reflecting Hiya’s lower gross margin mix and higher “Other.”
Direct selling net sales fell as active customers decreased to 388,000, with broad softness across Asia Pacific and Americas/Europe. Cash and cash equivalents were $145.3 million and there was no balance on the $75 million revolver at quarter‑end. Year to date, USANA repurchased 927,000 shares for $27.7 million, leaving $34.0 million authorized. As of October 31, 2025, shares outstanding were 18,280,857. Subsequently, the company initiated a cost alignment program with an expected $4.7 million one‑time Q4 charge.
USANA Health Sciences (USNA) director reported a sale of 1,057 shares of common stock (Code S) at $21.4799 on 11/03/2025. Following the transaction, the director beneficially owned 0 shares, held as direct ownership (D).
USANA Health Sciences (USNA) reported an insider transaction on a Form 4. A company director sold 1,750 shares of Common Stock on 10/31/2025 at a price of $19.79 per share (transaction code: S for open-market sale). After this trade, the insider directly beneficially owns 4,565 shares.
USANA Health Sciences (USNA) — director Form 4 activity. On 10/23/2025, 1,057 shares of common stock were acquired via the vesting/settlement of restricted stock units (code M). To cover taxes, 606 shares were withheld/disposed at $20.63 (code F). Following these transactions, the director directly owned 4,586 shares. The related RSU award had a $0 exercise price and continues to vest in scheduled 25% installments on specified dates.
USANA Health Sciences (USNA) reported an insider transaction by a director on 10/23/2025. The filing shows the conversion of restricted stock units into 1,057 shares of common stock (Transaction Code M) and a separate Code F disposition of 265 shares at $20.63 per share.
Following these transactions, the reporting person directly held 9,027 shares of common stock and 2,115 restricted stock units. The RSUs vest in four 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
FAQ
What is the current stock price of Usana Health Sciences (USNA)?
What is the market cap of Usana Health Sciences (USNA)?
